Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026 - … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product …
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026 - … disease; the potential of Biogen’s commercial business and pipeline programs, including diranersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … disease; the potential of Biogen’s commercial business and pipeline programs, including diranersen; and risks and …
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026 - … the global opportunity for felzartamab, a potential pipeline-in-a-product with broad applicability across a range … Bio, supporting continued investment in our differentiated pipeline while enabling us to participate in the future … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated …
… 2.7 MB Sep 3, 2025 10:00 AM EDT Biogen Thematic Pipeline Seminar: Lupus Listen to webcast Biogen Thematic Pipeline Seminar: Lupus 2.5 MB Pagination Current page 1 Page … 2.7 MB Sep 3, 2025 10:00 AM EDT Biogen Thematic Pipeline Seminar: Lupus Listen to webcast Biogen Thematic …
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026 - … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement … and EMPAVELI ® – to patients and building an innovative pipeline leveraging our deep expertise in complement …
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026 - … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and …
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
March 28, 2026 - … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and …
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
March 20, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
March 19, 2026 - … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and …
